We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Lunglife Ai Inc | LSE:LLAI | London | Ordinary Share | ORD USD0.0001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -0.69% | 14.40 | 13.80 | 15.00 | 14.50 | 14.40 | 14.50 | 19,886 | 09:42:13 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMLLAI
RNS Number : 0177G
LungLife AI, INC
15 November 2022
LungLife AI, Inc.
("LungLife" or the "Company")
Block Listing Six Monthly Return
LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six-monthly update on its block listing:
Name of applicant: LungLife AI, Inc. Name of scheme: 1. 2010 Stock Incentive Plan 2. 2020 Stock Incentive Plan 3. 2021 Omnibus Long-Term Incentive Plan ---------------------------------------------- Number and class of securities 1,356,139 common shares of US originally admitted: $0.0001 each ---------------------------------------------- Date of admission: 15 November 2021 ---------------------------------------------- Period of return: From: 15 May 2022 To: 15 November 2022 ------- ----------------- ----- -------------------- Balance of unallotted securities 1. 480,775 under scheme(s) from previous return: 2. 201,374 3. 673,990 ---------------------------------------------- Plus: The amount by which the 1. NIL block scheme(s) has been increased 2. NIL since the date of the last 3. NIL return (if any increase has been applied for): ---------------------------------------------- Less: Number of securities 1. 5,192 issued/allotted under scheme(s) during period (see LR3.5.7G): 2. NIL 3. NIL ---------------------------------------------- Equals: Balance under scheme(s) 1. 475,583 not yet issued/allotted at end of period: 2. 201,374 3. 673,990 ---------------------------------------------- Name of contact: David Anderson, Chief Financial Officer Telephone number of contact: + 44 (0)20 7933 8780 or lunglifeai@walbrookpr.com --------------------------------------------------
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com Paul Pagano, CEO Via Walbrook PR David Anderson, CFO Investec Bank plc (Nominated Tel: +44 (0)20 7597 5970 Adviser & Broker) Daniel Adams / Virginia Bull / Cameron MacRitchie Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654 / / Phil Marriage +44 07867 984 082
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRGPGUUGUPPGPU
(END) Dow Jones Newswires
November 15, 2022 02:00 ET (07:00 GMT)
1 Year Lunglife Ai Chart |
1 Month Lunglife Ai Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions